Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Capsicum Oleoresin→

Capsicum Oleoresin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8023-77-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Capsaicinoid-containing botanical extracttopical counterirritant and analgesic ingredient
Mechanism of action
Capsaicinoids activate TRPV1 on peripheral sensory neurons and, with repeated exposure, produce functional desensitisation and reduced nociceptive signalling. Extract composition and capsaicin concentration vary by botanical source and formulation.
Indications / reported uses
  • Topical symptomatic relief of minor muscle and joint pain in external analgesic products
  • Where standardised capsaicinoid products are authorised, use for selected localised neuropathic pain; do not assume all oleoresin formulations have equivalent potency or indications

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · PubMed — Capsicum oleoresin topical analgesia · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Capsicum Oleoresin Environmental Risk Assessment (ERA) (the Capsicum Oleoresin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.